MTNB (Matinas BioPharma Holdings) ROE % Adjusted to Book Value: -184.64% (As of Mar. 2026)


MTNB Matinas BioPharma Holdings Inc MTNB
30 GF Score
Price $0.64
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings ROE % Adjusted to Book Value?

Matinas BioPharma Holdings MTNB +3.15% 30 ROE % Adjusted to Book Value is -184.64% as of Mar. 2026. GuruFocus rates MTNB with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Matinas BioPharma Holdings's ROE % for the quarter that ended in Mar. 2026 was -195.72%. Matinas BioPharma Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 1.06. Matinas BioPharma Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -184.64%.

Matinas BioPharma Holdings ROE % Adjusted to Book Value Related Terms

Matinas BioPharma Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Matinas BioPharma Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Matinas BioPharma Holdings ROE % Adjusted to Book Value Chart

Matinas BioPharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.63 -15.92 -33.65 -531.56 -213.58

Matinas BioPharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.57 -510.00 -50.12 -173.69 -184.64

MTNB vs DRMA, MBIO, ADIL: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Matinas BioPharma Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Matinas BioPharma Holdings ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's ROE % Adjusted to Book Value falls into.


MTNB
30GF Score
Matinas BioPharma Holdings Inc MTNB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Matinas BioPharma Holdings ROE % Adjusted to Book Value Calculation

Matinas BioPharma Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-166.59% / 0.78
=-213.58%

Matinas BioPharma Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-195.72% / 1.06
=-184.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -184.64% mean?
Matinas BioPharma Holdings (MTNB) has a ROE % Adjusted to Book Value of -184.64% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Matinas BioPharma Holdings and its competitors.
Is Matinas BioPharma Holdings' ROE % Adjusted to Book Value too high?
Matinas BioPharma Holdings' current ROE % Adjusted to Book Value is -184.64%. Overall, Matinas BioPharma Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' ROE % Adjusted to Book Value compare to DRMA and MBIO?
Matinas BioPharma Holdings' ROE % Adjusted to Book Value of -184.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current ROE % Adjusted to Book Value is -184.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current ROE % Adjusted to Book Value of -184.64%. The current ROE % Adjusted to Book Value is -184.64%. Matinas BioPharma Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current ROE % Adjusted to Book Value is -184.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
30GF Score

Get the complete analysis for MTNB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price